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Risk assessment model for ﬁrst-cycle chemotherapy-induced neutropenia in patients with solid tumours
Chemotherapy-induced neutropenia, the major dose-limiting toxicity of chemotherapy, is directly associated
with concomitant morbidity, mortality and health-care costs. The use of prophylactic granulocyte colony-
stimulating factors may reduce the incidence and duration of chemotherapy-induced neutropenia, and is
recommended in high-risk patients. The objective of this study was to develop a model to predict ﬁrst-cycle
chemotherapy-induced neutropenia (deﬁned as neutropenia grade 3, with or without body temperature
38°C) in patients with solid tumours. A total of 1194 patients [56% women; mean age 58  12 years; 94%
Eastern Cooperative Oncology Group (ECOG) status 1] with solid tumours were included in a multi-centre
non-interventional prospective cohort study. A predictive logistic regression model was developed. Several
factors were found to inﬂuence chemotherapy-induced neutropenia. Higher ECOG status values increased
toxicity (ECOG 2 vs. 0, P = 0.003; odds ratio 3.12), whereas baseline lymphocyte (P = 0.011; odds ratio 0.67) and
neutrophil counts (P = 0.026; odds ratio 0.90) were inversely related to neutropenia occurrence. Sex and
treatment intention also signiﬁcantly inﬂuenced chemotherapy-induced neutropenia (P = 0.012). The sensi-
tivity and speciﬁcity of the model were 63% and 67% respectively, and the positive and negative predictive
values were 17% and 94% respectively. Once validated, this model should be a useful tool for clinical decision
making.
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INTRODUCTION
Patients receiving myelosuppressive chemotherapy fre-
quently develop severe neutropenia or febrile neutropenia.
Myelosuppressive chemotherapy regimens are regularly
used to treat a wide variety of malignancies, and
chemotherapy-induced neutropenia is one of the major
dose-limiting toxicities seen in clinical oncology practice.
Neutropenia, and more speciﬁcally febrile neutropenia,
are clinically relevant issues with a negative impact on
quality of life, causing increased morbidity and mortality
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Pizzo et al. 1986; Talcott et al. 1992; Hughes et al. 2002).
In future, chemotherapy-induced neutropenia will
become an even greater issue as elderly populations
increase in developed countries, leading to a higher preva-
lence of cancers and an increase in the age-related risk of
chemotherapy-induced neutropenia (Lyman et al. 2003).
The reported incidence and prevalence of neutropenia
vary widely. One of the most reliable estimates cited in
the literature suggests an incidence of 7.83 neutropenic
hospitalisations per 1000 cancer patients (Caggiano et al.
2005). However, neutropenia has been observed in 6–50%
of patients, depending on the cancer type, disease staging,
patient functional status and chemotherapy regimen
(Smith et al. 2006). In the USA, reported inpatient mor-
tality rates associated with grades 3 and 4 neutropenia
range from 3.4% to 10.5%, with an overall mortality
ranging from 6.8% to 9.5% (Crawford et al. 2004; Cag-
giano et al. 2005; Kuderer et al. 2006).
Toxicity during the ﬁrst chemotherapy cycle is an
important indicator of future neutropenic events, toler-
ance to chemotherapy and overall disease response.
Several studies have shown that patients with poor che-
motherapy tolerance and associated complications during
the ﬁrst cycle ultimately have a worse clinical outcome
than their counterparts without such adverse responses
(Blay et al. 1996; Crawford et al. 2004). This variability is
probably related to modiﬁcations of planned chemo-
therapy treatments, such as decreasing the chemotherapy
dose, increasing the interval between cycles, changing
chemotherapeutic agents and possibly even stopping
treatment completely. These alterations usually diminish
the response rate and the patient’s overall survival (Dixon
et al. 1986; Kwak et al. 1990; Lepage et al. 1993; Bona-
donna et al. 1995; Chrischilles et al. 2003; Lyman &
Delgado 2003).
For several years, physicians have used prophylactic
granulocyte colony-stimulating factors to reduce the
incidence and duration of chemotherapy-induced
neutropenia/febrile neutropenia, thus improving the
patient’s quality of life (Fazio & Glaspy 1991; Padilla &
Ropka 2005) and reducing the rate of associated compli-
cations, such as prolonged hospitalisation (Vogel et al.
2005) and empiric use of broad-spectrum antibiotics.
However, granulocyte colony-stimulating factors treat-
ment is not administered to all patients at high risk of
neutropenia receiving chemotherapy because of its cost
and a paucity of conclusive studies for some diseases and
chemotherapy regimens. Nevertheless, the guidelines of
the American Society of Clinical Oncology and of the
European Organization for Research and Treatment of
Cancer, which are based on the best evidence currently
available, recommend the use of granulocyte colony-
stimulating factors primary prophylaxis when the overall
risk of febrile neutropenia from chemotherapy and
patient-related factors (e.g. age, advanced disease) is 20%
(Aapro et al. 2006; Smith et al. 2006). However, despite
these recommendations, both sets of guidelines recognise
the need for better tools to improve the risk assessment of
chemotherapy-induced neutropenia.
Since the early years of systemic chemotherapy, efforts
have been made to create a model or tool for predicting
chemotherapy-induced neutropenia that would allow the
stratiﬁcation of patients and treatments according to risk
proﬁles. The literature contains numerous studies and
small case series that have led to the development of such
models for speciﬁc neoplasias (e.g. non-Hodgkin’s lym-
phoma, breast cancer, lung cancer) or chemotherapy regi-
mens (Blay et al. 1996; Silber et al. 1998; Klastersky et al.
2000; Lyman 2000; Ray-Coquard et al. 2003; Savvides
et al. 2003). One of the most comprehensive reviews of
these risk-model studies identiﬁed common factors of the
14 models proposed for chemotherapy-induced neutrope-
nia, including age, performance status, nutritional status,
chemotherapy dose intensity and baseline blood cell
counts. Unfortunately, conclusive results were limited
because of the different study designs, small patient
numbers and diverse chemotherapy regimens used in
these studies (Silber et al. 1998; Aslani et al. 2000; Intra-
gumtornchai et al. 2000; Voog et al. 2000; Savvides et al.
2003). The development of a risk assessment model for
chemotherapy-induced neutropenia in patients with solid
tumours remains a priority. In this article, we present our
preliminary results in developing such a model, based on
data from the DELFOS study.
METHODS
Study design
The DELFOS study was a multi-centre, prospective, non-
interventional cohort study undertaken in Spain to assess
the haematological toxicity risk in patients with solid
tumours during their ﬁrst three chemotherapy cycles. The
chemotherapy regimen administered to each patient was
determined on the basis of normal clinical practice.
Patients were included in the study over a 10-month
period from 15 March 2004 to 5 January 2005. Patient data
were recorded before each of their ﬁrst three chemo-
therapy cycles, after the third chemotherapy cycle, and
one year after chemotherapy initiation. All data were veri-
ﬁed by qualiﬁed personnel.
Risk assessment model
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649The study was approved by the ethical review boards of
all participating centres and was sponsored by the Spanish
Society of Medical Oncology. All patients gave their
written informed consent.
Inclusion criteria
Eligible patients were adults (aged 18 years) with a
histologically conﬁrmed solid tumour who had not
previously received chemotherapy, with an Eastern
Cooperative Oncology Group (ECOG) performance status
score of 2, and a good bone marrow reserve. Liver and
kidney functions were required to be within clinically
acceptable ranges for this patient population: bilirubin
<1.5 times higher than the normal value; aspartate ami-
notransferase and alanine transaminase <3 times higher
than the normal range (both could be 5 times higher than
normal in patients with known hepatic metastasis); and
creatinine <1.5 times higher than the normal value. Che-
motherapy was administered only via the intravenous
route or via intravenous in combination with oral
administration.
Exclusion criteria
Pregnant or breast feeding women were excluded from
participation in the study. Patients with previous bone
marrow or stem cell transplantation or patients in whom
high-dose chemotherapy or bone marrow or stem cell
transplantation was anticipated in the 12 weeks following
inclusion in the study were also excluded. Patients with
an active infection or in receipt of an antibiotic in the 72 h
before chemotherapy were also excluded, as were those
with myeloid premalignant disease or malignant disease
with myeloid characteristics, disease producing leukope-
nia, thrombocytopenia, or anaemia, and those who were
receiving daily chemotherapy regimens or chemotherapy
via a route other than intravenous or intravenous plus oral
administration.
Assessments
Each patient was assessed with regard to a number of
demographic and disease-related variables that potentially
inﬂuence chemotherapy-induced neutropenia. These in-
cluded sex, body surface area, age-adjusted Charlson
score, ECOG performance status score, baseline lympho-
cyte, neutrophil and platelet counts, baseline haemoglo-
bin, bilirubin, creatinine, aspartate aminotransferase and
alanine aminotransferase levels, treatment intention, and
tumour-related variables (i.e. TNM stage). Neutropenia,
deﬁned as an absolute neutrophil count of <1 ¥ 109/L
(Grade 3) or absolute neutrophil count <0.5 ¥ 109/L (Grade
4), was the main outcome variable studied. Febrile neu-
tropenia was deﬁned as severe neutropenia (Grade 4) with
a body temperature of >38°C (Lyman et al. 2005). The
blood test results were collected before each chemo-
therapy cycle, together with other tests requested by the
physicians between the ﬁrst and third chemotherapy
cycles. No planned blood cell counts were performed at
the cycle nadir.
Statistical analysis
Descriptive analyses were used to construct the popula-
tion proﬁle and a variety of bivariate tests were performed
to explore potential relationships between the indepen-
dent pools of socio-demographic and clinical variables and
chemotherapy-induced neutropenia in the population. A
prediction tool was developed using a modelling process
that incorporated clinically relevant second-order interac-
tions between the variables. The hierarchical principle
was applied when building the logistic regression model to
allow result replication. This principle, applied to model
building, states that when the interaction of two factors is
signiﬁcant, the individual factors must remain in the
model (even if one or both factors are not statistically
signiﬁcant). The results are presented as odds ratios
and 95% conﬁdence intervals for variables in the
chemotherapy-induced neutropenia prediction model, to
provide information about their effect measure and its
precision. The forward stepwise (Wald) decision process
was used to determine the variables in the ﬁnal model,
and the input and output probability criteria for the vari-
ables were 0.05 and 0.1 respectively. A receiver operating
characteristic curve was used to determine the cut-off
point at which the sensitivity and speciﬁcity values for
the model were maximised. All statistical operations were
performed using the SPSS statistical software package,
v12.
RESULTS
Patients were enrolled and followed up between March
2004 and May 2006. A total of 1194 patients from 88
different oncology centres were enrolled. Their mean age
was 58  12 (SD) years, and 56% were women. Ninety-
four per cent of the patients had a good initial performance
status (ECOG 0–1). Breast (38%), lung (18%) and colorec-
tal (15%) cancers were the most frequent cancers. Treat-
ment intention was primarily radical, adjuvant or
palliative. The most frequent chemotherapy regimens
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650were platinum or anthracycline based. A minority of
patients received concomitant radiotherapy (see Table 1).
The incidence of grades 3–4 neutropenia was 10% (conﬁ-
dence interval 8.3–11.8; n = 116) during the ﬁrst cycle of
chemotherapy in our study population.
Model development
From all the demographic and disease characteristics
assessed, baseline lymphocyte and neutrophil counts,
ECOG performance status and the interaction between
sex and treatment intention were found to inﬂuence
chemotherapy-induced neutropenia and were included in
the predictive model (see Table 2). The overall model sig-
niﬁcance was P < 0.0005.
The baseline lymphocyte count was inversely related to
the risk of chemotherapy-induced neutropenia in the ﬁrst
cycle (odds ratio, 0.67; 95% conﬁdence interval, 0.49–
0.91), as was the baseline neutrophil count (odds ratio,
0.90; 95% conﬁdence interval, 0.82–0.99). Patients with
an ECOG status of 2 at baseline had a higher risk of
chemotherapy-induced neutropenia in the ﬁrst cycle
than did patients with an ECOG of 0 (odds ratio, 3.12;
95% conﬁdence interval, 1.46–6.68), and patients with
neo-adjuvant treatment intention had a lower risk of
chemotherapy-induced neutropenia than those whose
treatment intention was palliative (odds ratio, 0.11; 95%
conﬁdence interval, 0.02–0.86). The interaction between
sex and treatment intention was also predictive of
chemotherapy-induced neutropenia.
A cut-off point of 0.101 on the receiver operating
characteristic curve provided maximal values for sensi-
tivity (63%) and speciﬁcity (67%). This cut-off point
maximises the true positives and the true negatives
of the equation (see Fig. 1 and Table 3). Using the
model equation in Figure 2, results 0.101 predicted
ﬁrst-cycle chemotherapy-induced neutropenia, whereas
results <0.101 predicted those patients in whom no
chemotherapy-induced neutropenia would occur. In our
study population, 36% of patients (n = 430) were identi-
ﬁed as at high risk of ﬁrst-cycle chemotherapy-induced
neutropenia and 64% (n = 764) as at low risk of grade 3
or 4 neutropenia. The positive predictive value (i.e.
patients having neutropenia when the model predicted
it) was 17% (95% conﬁdence interval, 13.6–21.4), and
the negative predictive value (i.e. patients who did not
develop neutropenia when the model predicted no neu-
tropenia) was 94% (95% conﬁdence interval, 92.2–95.9).
The sensitivity and speciﬁcity of the predictive risk
model for ﬁrst-cycle chemotherapy-induced neutropenia
were 63% and 67% respectively.
DISCUSSION
Two basic types of models have been developed to predict
neutropenia, which can be found in the literature: condi-
tional models, which are based on patient toxicity during
the ﬁrst chemotherapy cycle, and unconditional models,
which are dependent on pretreatment values (Crawford
et al. 2004; Lyman et al. 2005). Our model is of the latter
type, and aims to predict (and therefore help to avoid) the
ﬁrst episode of neutropenia. Neutropenic complications
are most likely to occur in the ﬁrst cycle of chemotherapy,
so unconditional models are more appropriate.
Table 1. Baseline characteristics of patients with solid tumours
included in the study
% n
Demographics
Age (years) (SD) 58  12 1194
Sex
Female 56 1194
Male 44
Clinical features
ECOG performance score
Score 0 62 1194
Score 1 32
Score 2 6
Tumour type
Breast 38 1194
Trachea, bronchi and/or lungs 18
Colon and rectum 15
Ovary 5
Stomach 5
Other tumours (incidence <3%) 20
Treatment intention
Palliative 28 1194
Radical curative 9
Radical neo-adjuvant 12
Radical adjuvant 51
Chemotherapy regimen
Platinum-based chemotherapy 29 1194
Taxane-based chemotherapy 9
Taxane + platinum-based
chemotherapy
14
Anthracycline-based chemotherapy 30
Other 18
Radiotherapy
None 61 1194
Sequential 30
Concomitant 9
Laboratory values mean  SD n
Haemoglobin (g/dL) 12.9  1.6 1190
Lymphocytes (10
9/L) 2.1  1.8 1190
Neutrophils (109/L) 5.3  3.2 1190
Platelets (10
9/L) 299.5  110.9 1190
Bilirubin (mg/dL) 0.5  0.5 1151
Aspartate aminotransferase (IU/L) 23.2  15.7 1175
Alanine transaminase (IU/L) 25.5  20 1184
Creatinine (mg/dL) 1.1  4.0 1189
ECOG, Eastern Cooperative Oncology Group; SD, standard
deviation.
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651The resulting logistic regression model was based on
four factors: (1) baseline neutrophil; (2) lymphocyte
counts, which were, as expected, inversely related to
neutropenia because of their relationship with the
patient’s bone marrow reserve (these factors have been
found to be useful in other risk models) (Silber et al.
1998; Rivera et al. 2003); (3) ECOG scores: higher ECOG
scores were associated with increased toxicity; and (4)
the interaction of sex and treatment intention (the latter
two factors were included because their interaction was
signiﬁcant). This interaction suggests different patterns
of chemotherapy-induced neutropenia risk according to
treatment intention in men and women, and may also be
a function of the large breast cancer subgroup in the
study, which constituted over one-third of the total
study population.
The incidence of chemotherapy-induced neutropenia in
the study population was 10%. With a positive predictive
value of 17%, the use of the model actually increases by
7% of the power to predict neutropenia in approximately
one-third of our population (i.e. those for whom the model
Table 2. Multivariate logistic regression model predicting chemotherapy-induced neutropenia in patients with solid tumours initiating
chemotherapy*
Beta-coefﬁcient P-value Odds ratio
95% conﬁdence interval
Lower Upper
Sex: male vs. female -0.586 0.164 0.557 0.244 1.269
Baseline lymphocyte count -0.400 0.011 0.670 0.492 0.913
Treatment intention 0.155
Radical adjuvant vs. palliative -0.434 0.274 0.648 0.298 1.410
Radical neo-adjuvant vs. palliative -2.178 0.035 0.113 0.015 0.858
Radical curative vs. palliative -0.319 0.509 0.727 0.282 1.874
Sex and treatment intention 0.012
Male and radical adjuvant 0.455 0.413 1.576 0.531 4.679
Male and radical neo-adjuvant 2.889 0.012 17.975 1.893 170.697
Male and radical curative 1.835 0.013 6.263 1.470 26.688
ECOG performance score 0.011
1 vs. 0 0.072 0.770 1.075 0.662 1.747
2 vs. 0 1.139 0.003 3.123 1.459 6.683
Baseline neutrophil count -0.104 0.026 0.901 0.823 0.987
*Model signiﬁcance (P = 0.0005, c2).
Model constant: beta-coefﬁcient =- 0.693, P = 0.139 and odds ratio = 0.500.
ECOG, Eastern Cooperative Oncology Group.
Figure 1. Determining model sensitivity and speciﬁcity with the
receiver operating characteristic curve (ROC).
Table 3. Discriminatory properties of the multivariate logistic regression model predicting chemotherapy-induced neutropenia
Observed in the study (gold standard)
Expected by the model
Chemotherapy-induced neutropenia
No Yes
Chemotherapy-induced neutropenia
No 654 321 975 (speciﬁcity: 67%)
Yes 40 67 107 (sensitivity: 63%)
694 (negative predictive
value: 94%)
388 (positive predictive
value: 17%)
1082 (overall correct: 67%)
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652predicts neutropenia). The model also increases to 94% of
the power to predict no neutropenia in the remainder
(64%) of the population (i.e. those for whom the model
predicts no risk of neutropenia). Therefore, in two-thirds
of the patients, a negative prediction could be useful in
reducing the chance of suffering neutropenia from 10% to
6% in the ﬁrst cycle. In a practical sense, the use of this
model will allow physicians to circumscribe their efforts
(closer follow-up and/or primary prophylaxis) to a smaller
group of patients at higher risk of developing
chemotherapy-induced neutropenia, while selecting out a
larger group of patient with no risk of chemotherapy-
induced neutropenia. To examine the model more closely,
we applied it to a population in which the incidence
of chemotherapy-induced neutropenia was about 20%,
and a positive predictive value of 32% was obtained
(data not shown), which represents an increase of 12% in
the predictive power of the model (as the sensitivity
and speciﬁcity of the model will not change in a real
population).
As previously mentioned, other risk models have iden-
tiﬁed several risk factors for the development of
chemotherapy-induced neutropenia/febrile neutropenia
and its related mortality. These models and risk factors
are disease speciﬁc (e.g. breast cancer, lung cancer, leu-
kaemia) or regimen oriented. Our model was developed in
a large adult population with diverse cancers and the data
were collected with the aim of identifying haematological
toxicities in general oncology practice. Therefore, we
believe that the present model represents a step forward,
providing a useful tool for the prediction of neutropenia in
normal oncology practice.
Two factors that have commonly been included in pre-
vious models were not included in our model: age and
chemotherapy regimen. Our justiﬁcation for the omis-
sion of age is that this factor showed collinearity with a
number of the other variables (such as lymphocyte
count, co-morbidity, ECOG status, chemotherapy, treat-
ment intention) during the modelling process. When age
was included, many other factors became insigniﬁcant,
indicating that age is a particularly strong predictive
factor for neutropenia, and thus excludes other variables
from the equation. Age is already a known risk factor for
the development of chemotherapy-induced neutropenia/
febrile neutropenia. Therefore, its omission is reason-
able. Furthermore, chronological age and biological age
can differ, and the results of some studies have suggested
that the measure of clinical frailty could be a risk factor
rather than age per se (Crawford et al. 2004). Our mod-
elling process for the equation seems to corroborate this,
because the ECOG functional status measure was iden-
tiﬁed as a signiﬁcant factor, although in our sample, the
majority of patients were only ECOG 0–1, with 6% of
patients ECOG 2, and none with higher values because
of the study design. Our main reasons for not including
the chemotherapy regimen in the model are the diversity
of regimens used for the treatment of non-speciﬁc
cancers and the evolution of those treatments as new
drugs are incorporated. Instead, we included treatment
intention, which potentially reﬂects the chemotherapy
dose administered. This model has only been assessed
against itself, so it must be validated before its use in a
clinical setting.
The large number of patients and the quality of the data
collected in the DELFOS study, the prospective design,
together with the diversity of patients and solid tumours
included in the study give this model a sound basis.
However, we acknowledge that it is difﬁcult to develop a
single model that ﬁts the diversity of patient characteris-
tics, diseases and chemotherapy regimens observed in our
sample. Future studies will focus on the validation of the
model in general and in speciﬁc oncological populations,
and also on the evaluation of its impact on morbidity,
mortality and economics.
CONCLUSION
This risk assessment model allows the identiﬁcation of
high- and low-risk patients before the initiation of chemo-
therapy. A prospective study must be performed to
validate it. The model represents a step forward in
chemotherapy-induced neutropenia risk management.
Figure 2. Logistic regression model equation for the prediction of ﬁrst-cycle chemotherapy-induced neutropenia. Sex (1), male; Lym,
baseline lymphocyte count; TI (1), treatment intention: radical adjuvant; TI (2), treatment intention: radical neo-adjuvant; TI (3),
treatment intention: radical curative; ECOG (1), 1; ECOG (2), 2; Neutrop, baseline neutrophil count. ECOG, Eastern Cooperative
Oncology Group.
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